ASKA Pharmaceutical Holdings Co.,Ltd.

4886

JP3119660003

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
2,117 ^JPY	-5.07%		-9.10%	+18.67%

2023	Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	CI
2023	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI

ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan.

July 11, 2021

The Board of Directors of ASKA Pharmaceutical Holdings Co.,Ltd. has authorized a buyback plan on July 12, 2021.

Latest news about ASKA Pharmaceutical Holdings Co.,Ltd.

Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	Dec. 20	CI
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.	22-03-24	CI
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million.	22-03-22	CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.	22-01-05	CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.	21-10-01	CI
ASKA Pharmaceutical Holdings Co.,Ltd. announces an Equity Buyback for 300,000 shares, representing 1.05% for ¥350 million.	21-07-12	CI
ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan.	21-07-11	CI
ASKA Pharmaceutical Holdings Co., Ltd. acquired 20.04% stake in Japan Glass Industry Co., Ltd.	21-04-22	CI
Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development	21-02-10	CI
ASKA Pharmaceutical Co., Ltd. acquired additional 20% stake in Ha Tay Pharmaceutical JSC.	21-02-03	CI
ASKA Pharmaceutical Co., Ltd. completed the acquisition of 24.9% stake in Ha Tay Pharmaceutical JSC.	21-01-14	CI
Ha Tay Pharmaceutical JSC announced that it has received VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd.	21-01-14	CI
Ha Tay Pharmaceutical JSC announced that it expects to receive VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. and other investors	20-09-13	CI
ASKA Pharmaceutical Co., Ltd. signed an agreement to acquire 24.9% stake in Ha Tay Pharmaceutical JSC.	20-08-17	CI
Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona	20-06-01	CI
ASKA Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2020, Payable on June 26, 2020; Provides Dividend Guidance for the Second Quarter and Year Ended March 31, 2021; Reports Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021	20-05-12	CI
ASKA Pharmaceutical Co., Ltd. and Kinopharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia	20-01-14	CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 2019; Provides Consolidated Earnings Guidance for the Year Ending March 2020	19-08-04	CI
ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited Enter into Licensing Agreement for Relugolix in Women's Health Indications	18-05-31	CI
Omnicare Drugs India Pvt. Ltd. and Aska Pharmaceuticals Co. Ltd. Enter into an Agreement to Establish A Joint Venture	18-04-30	CI
ASKA Pharmaceutical and Neopharma Agree to Establish a Joint Venture in India	18-04-19	CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Ending March 31, 2018	17-11-05	CI
ASKA Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Second Quarter Ending September 2017 and for the Full Year Ending March 2018	17-08-06	CI
TesoRx Pharma LLC and ASKA Pharmaceutical Co., Ltd. Announce TSX-011 (Oral Testosterone) Proceeding to Human Studies Following Successful PK Study Results	17-04-27	CI

Chart ASKA Pharmaceutical Holdings Co.,Ltd.

Duration

Period

Chart ASKA Pharmaceutical Holdings Co.,Ltd.

More charts

ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for ASKA Pharmaceutical Holdings Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,117 JPY

Average target price

2,667 JPY

Spread / Average Target

+25.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASKA PHARMACEUTICAL HOLDINGS CO.,LTD.	+18.67%	409M
ELI LILLY AND COMPANY	+33.21%	700B
JOHNSON & JOHNSON	-4.95%	358B
MERCK & CO., INC.	+18.69%	330B
ABBVIE INC.	+3.33%	287B
ASTRAZENECA PLC	+15.70%	236B
NOVARTIS AG	+6.68%	202B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+5.45%	161B
PFIZER, INC.	-2.31%	157B

Other Pharmaceuticals